Analysis of illegitimate genomic integration mediated by zinc-finger nucleases: implications for specificity of targeted gene correction.
BACKGROUND
Formation of site specific genomic double strand breaks (DSBs), induced by the expression of a pair of engineered zinc-finger nucleases (ZFNs), dramatically increases the rates of homologous recombination (HR) between a specific genomic target and a donor plasmid. However, for the safe use of ZFN induced HR in practical applications, possible adverse effects of the technology such as cytotoxicity and genotoxicity need to be well understood. In this work, off-target activity of a pair of ZFNs has been examined by measuring the ratio between HR and illegitimate genomic integration in cells that are growing exponentially, and in cells that have been arrested in the G2/M phase.


RESULTS
A reporter cell line that contained consensus ZFN binding sites in an enhanced green fluorescent protein (EGFP) reporter gene was used to measure ratios between HR and non-homologous integration of a plasmid template. Both in human cells (HEK 293) containing the consensus ZFN binding sites and in cells lacking the ZFN binding sites, a 3.5 fold increase in the level of illegitimate integration was observed upon ZFN expression. Since the reporter gene containing the consensus ZFN target sites was found to be intact in cells where illegitimate integration had occurred, increased rates of illegitimate integration most likely resulted from the formation of off-target genomic DSBs. Additionally, in a fraction of the ZFN treated cells the co-occurrence of both specific HR and illegitimate integration was observed. As a mean to minimize unspecific effects, cell cycle manipulation of the target cells by induction of a transient G2/M cell cycle arrest was shown to stimulate the activity of HR while having little effect on the levels of illegitimate integration, thus resulting in a nearly eight fold increase in the ratio between the two processes.


CONCLUSIONS
The demonstration that ZFN expression, in addition to stimulating specific gene targeting by HR, leads to increased rates of illegitimate integration emphasizes the importance of careful characterization of ZFN treated cells. In order to reduce off-target events, reversible cell cycle arrest of the target cells in the G2/M phase is an efficient way for increasing the ratio between specific HR and illegitimate integration.
Olsen
Petter A
PA
Section for Cellular and Genetic Therapy, Institute of Microbiology, Oslo University Hospital, Rikshospitalet, Gausdadalleen 21, 0349 Oslo, Norway. petter.angell.olsen@rr-research.no
Gelazauskaite
Monika
M
Randøl
Markus
M
Krauss
Stefan
S
D002453:Cell Cycle; D002460:Cell Line; D003851:Deoxyribonucleases / Q000737:chemistry / Q000378:metabolism*; D049452:Green Fluorescent Proteins / Q000378:metabolism; D006801:Humans; D015202:Protein Engineering; D016335:Zinc Fingers
C485184:enhanced green fluorescent protein; D049452:Green Fluorescent Proteins; D003851:Deoxyribonucleases
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):11997-2002
14514889
DNA Repair (Amst). 2007 Jul 1;6(7):923-35
17363343
Genes Dev. 2004 Jun 1;18(11):1293-304
15175261
Nat Biotechnol. 2009 Sep;27(9):851-7
19680244
Nature. 1985 Sep 19-25;317(6034):230-4
2995814
Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1156-60
8577732
Mol Cell Biol. 2003 May;23(10):3558-65
12724414
Mol Cell Biol. 1994 Dec;14(12):8096-106
7969147
Mol Cell Biol. 2001 Jan;21(1):289-97
11113203
Curr Med Chem Anticancer Agents. 2005 Jul;5(4):363-72
16101488
Cell Res. 2008 Jan;18(1):134-47
18157161
Nature. 2005 Jun 2;435(7042):646-51
15806097
Curr Gene Ther. 2006 Aug;6(4):481-504
16918336
Biochem Biophys Res Commun. 2005 Sep 9;334(4):1191-1197
16043120
Nature. 2000 Jun 8;405(6787):697-700
10864328
Mol Cell Biol. 1997 Jan;17(1):267-77
8972207
Science. 2009 Jul 24;325(5939):433
19628861
Nat Biotechnol. 2007 Jul;25(7):778-85
17603475
Oncogene. 2008 Mar 13;27(12):1726-36
17891177
Nature. 2009 May 21;459(7245):442-5
19404258
Cell Stem Cell. 2009 Jul 2;5(1):97-110
19540188
Cell. 1987 Nov 6;51(3):503-12
2822260
Nat Biotechnol. 2008 Jul;26(7):808-16
18587387
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16370-5
17060623
Nat Biotechnol. 2008 Jun;26(6):702-8
18500334
Environ Mol Mutagen. 2003;42(4):288-98
14673874
Mol Ther. 2008 Jul;16(7):1200-1207
28178480
Nat Biotechnol. 2007 Nov;25(11):1298-306
17965707
DNA Repair (Amst). 2009 Mar 1;8(3):298-308
19071233
DNA Repair (Amst). 2003 Oct 7;2(10):1147-56
13679152
Science. 2003 May 2;300(5620):764
12730594
Nucleic Acids Res. 2001 Oct 1;29(19):3975-81
11574679
Genetics. 2002 Jul;161(3):1169-75
12136019
Proc Natl Acad Sci U S A. 1988 Aug;85(16):6022-6
2842757
Nature. 2000 Nov 23;408(6811):433-9
11100718
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10570-5
9724744
Nat Biotechnol. 2007 Jul;25(7):786-93
17603476
Genetics. 2006 Apr;172(4):2391-403
16452139
Mol Cell. 2007 Dec 14;28(5):739-45
18082599
Mol Cell. 2008 Jul 25;31(2):294-301
18657511
J Mol Med (Berl). 2008 Nov;86(11):1205-19
18607557
Genome Res. 2009 Jul;19(7):1279-88
19470664
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1437-41
11171969
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13296-301
12271125
Mol Ther. 2006 Feb;13(2):438-46
16169774
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5172-7
9560248
Trends Biotechnol. 2005 Aug;23(8):407-19
15993503
Nature. 2009 May 21;459(7245):437-41
19404259
Gene Ther. 2008 Nov;15(22):1463-8
18784746
Nucleic Acids Res. 1990 Jun 25;18(12):3587-96
2194165
DNA Repair (Amst). 2005 Aug 15;4(9):1038-46
15935739
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8403-10
11459982
Nat Methods. 2008 May;5(5):374-5
18446154
Exp Cell Res. 1980 Apr;126(2):397-405
6153987
Mol Cell Biol. 2000 Dec;20(23):9068-75
11074004
Trends Genet. 1996 Jun;12(6):224-8
8928227
Nat Methods. 2010 Feb;7(2):91; author reply 91-2
20111032
Nat Biotechnol. 2008 Jun;26(6):695-701
18500337
Science. 2003 May 2;300(5620):763
12730593
Mol Ther. 2005 Oct;12(4):610-7
16039907
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3055-60
17360608
Mol Ther. 2008 Apr;16(4):707-17
18334988
J Cell Sci. 2004 Oct 1;117(Pt 21):4935-45
15367581
Mol Ther. 2008 Feb;16(2):352-358
28178540
Mol Ther. 2010 Apr;18(4):743-53
20068556